Analytical methods for process and product characterization of recombinant adeno-associated virus-based gene therapies

[1]  R. Puri,et al.  Clinical Development of Gene Therapies: The First Three Decades and Counting , 2020, Molecular therapy. Methods & clinical development.

[2]  Toshimitsu Tanaka,et al.  Optimization of the quality by design approach for gene therapy products: a case study for adeno-associated viral vectors. , 2020, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[3]  J. Sheng,et al.  Creation of a High-Yield AAV Vector Production Platform in Suspension Cells Using a Design-of-Experiment Approach , 2020, Molecular therapy. Methods & clinical development.

[4]  P. Alves,et al.  Holographic Imaging of Insect Cell Cultures: Online Non-Invasive Monitoring of Adeno-Associated Virus Production and Cell Concentration , 2020, Processes.

[5]  S. DeVries,et al.  Quantification of Adeno-Associated Virus with Safe Nucleic Acid Dyes , 2020, bioRxiv.

[6]  R. Samulski,et al.  Engineering adeno-associated virus vectors for gene therapy , 2020, Nature Reviews Genetics.

[7]  P. Kukura,et al.  Single molecule mass photometry of nucleic acids , 2020, bioRxiv.

[8]  Hongshan Li,et al.  Rapid, Automated, At-Line AAV2 Virus Quantitation Advances Bioprocessing in Gene Therapy AAV2 Virus Binding and Standard Curve Generation AAV2 Virus Quantitation , 2020 .

[9]  Weibin Chen,et al.  Anion-Exchange Chromatography for Determining Empty and Full Capsid Contents in Adeno-Associated Virus , 2020 .

[10]  Zhi-Yao He,et al.  The approved gene therapy drugs worldwide: from 1998 to 2019. , 2019, Biotechnology advances.

[11]  K. Müller,et al.  Adeno-associated virus capsid protein expression in Escherichia coli and chemically defined capsid assembly , 2019, Scientific Reports.

[12]  SubramanianSuriyasri,et al.  Filling Adeno-Associated Virus Capsids: Estimating Success by Cryo-Electron Microscopy , 2019, Human Gene Therapy.

[13]  Rui M. C. Portela,et al.  Enabling PAT in insect cell bioprocesses: In situ monitoring of recombinant adeno‐associated virus production by fluorescence spectroscopy , 2019, Biotechnology and bioengineering.

[14]  T. Linke,et al.  Developing an Anion Exchange Chromatography Assay for Determining Empty and Full Capsid Contents in AAV6.2 , 2019, Molecular therapy. Methods & clinical development.

[15]  D. Pimentel,et al.  Production of adeno-associated virus vectors for in vitro and in vivo applications , 2019, Scientific Reports.

[16]  Wei-Chiang Chen,et al.  Analytical strategies for quantification of adeno-associated virus (AAV) empty capsids to support process development. , 2019, Human gene therapy methods.

[17]  E. Uchida,et al.  Two-Dimensional Droplet Digital PCR as a Tool for Titration and Integrity Evaluation of Recombinant Adeno-Associated Viral Vectors , 2019, Human gene therapy methods.

[18]  Hyunmi Lee,et al.  Accurate Quantification and Characterization of Adeno-Associated Viral Vectors , 2019, Front. Microbiol..

[19]  Mario Schelhaas,et al.  Virus-like particle size and molecular weight/mass determination applying gas-phase electrophoresis (native nES GEMMA) , 2019, Analytical and Bioanalytical Chemistry.

[20]  M. Lock,et al.  Stability of the adeno-associated virus 8 reference standard material , 2019, Gene Therapy.

[21]  J. Schrag,et al.  Achieving High-Yield Production of Functional AAV5 Gene Delivery Vectors via Fedbatch in an Insect Cell-One Baculovirus System , 2019, Molecular therapy. Methods & clinical development.

[22]  Daniel R. Blessing,et al.  Scalable Production of AAV Vectors in Orbitally Shaken HEK293 Cells , 2018, Molecular therapy. Methods & clinical development.

[23]  L. Vandenberghe,et al.  Quantitative and Digital Droplet-Based AAV Genome Titration. , 2019, Methods in molecular biology.

[24]  A. Tamaoka,et al.  Highly Efficient Ultracentrifugation-free Chromatographic Purification of Recombinant AAV Serotype 9 , 2018, Molecular therapy. Methods & clinical development.

[25]  E. Ayuso,et al.  Accurate Titration of Infectious AAV Particles Requires Measurement of Biologically Active Vector Genomes and Suitable Controls , 2018, Molecular therapy. Methods & clinical development.

[26]  Daniel C. Cole,et al.  Quantitative mass imaging of single biological macromolecules , 2018, Science.

[27]  C. Heiner,et al.  Adeno-associated Virus Genome Population Sequencing Achieves Full Vector Genome Resolution and Reveals Human-Vector Chimeras , 2018, Molecular therapy. Methods & clinical development.

[28]  E. Ayuso,et al.  Pharmacology of Recombinant Adeno-associated Virus Production , 2018, Molecular therapy. Methods & clinical development.

[29]  Seng H. Cheng,et al.  Universal Method for the Purification of Recombinant AAV Vectors of Differing Serotypes , 2017, Molecular therapy. Methods & clinical development.

[30]  J Lizbeth Reyes Zamora,et al.  Flow virometry as a tool to study viruses. , 2017, Methods.

[31]  U. Gottschalk,et al.  New Bioprocessing Strategies: Development and Manufacturing of Recombinant Antibodies and Proteins , 2018 .

[32]  Determination of adenovirus concentration using Biacore T200 , 2018 .

[33]  Marco Jenzsch,et al.  Trends in Process Analytical Technology: Present State in Bioprocessing. , 2018, Advances in biochemical engineering/biotechnology.

[34]  A. Shukla,et al.  High-Throughput Process Development for Biopharmaceuticals. , 2018, Advances in biochemical engineering/biotechnology.

[35]  S. Crosson,et al.  Direct Head-to-Head Evaluation of Recombinant Adeno-associated Viral Vectors Manufactured in Human versus Insect Cells. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[36]  Kristen A. Severson,et al.  Opportunities and challenges of real‐time release testing in biopharmaceutical manufacturing , 2017, Biotechnology and bioengineering.

[37]  Rejane L Petersen.  Strategies Using Bio-Layer Interferometry Biosensor Technology for Vaccine Research and Development , 2017, Biosensors.

[38]  Manuel J T Carrondo,et al.  Universal label-free in-process quantification of influenza virus-like particles. , 2017, Biotechnology journal.

[39]  H. Büning,et al.  Improving the Quality of Adeno-Associated Viral Vector Preparations: The Challenge of Product-Related Impurities , 2017 .

[40]  H. Germain,et al.  Droplet Digital PCR versus qPCR for gene expression analysis with low abundant targets: from variable nonsense to publication quality data , 2017, Scientific Reports.

[41]  B. Cogné,et al.  Accurate Identification and Quantification of DNA Species by Next-Generation Sequencing in Adeno-Associated Viral Vectors Produced in Insect Cells. , 2017, Human gene therapy methods.

[42]  R. Kotin,et al.  Manufacturing Clinical Grade Recombinant Adeno-Associated Virus Using Invertebrate Cell Lines. , 2017, Human gene therapy.

[43]  A. Kamen,et al.  Manufacturing of recombinant adeno‐associated viruses using mammalian expression platforms , 2017, Biotechnology journal.

[44]  Aleksandar Sebesta,et al.  Label-Free Single-Molecule Imaging with Numerical-Aperture-Shaped Interferometric Scattering Microscopy , 2016, ACS photonics.

[45]  G. Massolini,et al.  Advances on Size Exclusion Chromatography and Applications on the Analysis of Protein Biopharmaceuticals and Protein Aggregates: A Mini Review , 2017, Chromatographia.

[46]  T. Weber,et al.  Production and Characterization of Vectors Based on the Cardiotropic AAV Serotype 9. , 2017, Methods in molecular biology.

[47]  H. Katus,et al.  Protocol for Efficient Generation and Characterization of Adeno-Associated Viral Vectors. , 2017, Human gene therapy methods.

[48]  Nadja Alt,et al.  Determination of critical quality attributes for monoclonal antibodies using quality by design principles. , 2016, Biologicals : journal of the International Association of Biological Standardization.

[49]  Helen Wu,et al.  Comparison of biosensor platforms in the evaluation of high affinity antibody-antigen binding kinetics. , 2016, Analytical biochemistry.

[50]  M. Jarrold,et al.  Resolving Adeno-Associated Viral Particle Diversity With Charge Detection Mass Spectrometry. , 2016, Analytical chemistry.

[51]  J. Grieger,et al.  Manufacturing of recombinant adeno-associated viral vectors for clinical trials , 2016, Molecular therapy. Methods & clinical development.

[52]  J. Grieger,et al.  Production of Recombinant Adeno-associated Virus Vectors Using Suspension HEK293 Cells and Continuous Harvest of Vector From the Culture Media for GMP FIX and FLT1 Clinical Vector. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[53]  Linshu Liu,et al.  High-Density Recombinant Adeno-Associated Viral Particles are Competent Vectors for In Vivo Transduction. , 2016, Human gene therapy.

[54]  D. Saunders,et al.  Influenza vaccine titer determination using biolayer interferometry (BLI) , 2015, BMC Proceedings.

[55]  Yongchang Cao,et al.  Rapid quantitation of porcine epidemic diarrhea virus (PEDV) by Virus Counter. , 2015, Journal of virological methods.

[56]  Seng H. Cheng,et al.  Analytical Ultracentrifugation as an Approach to Characterize Recombinant Adeno-Associated Viral Vectors. , 2015, Human gene therapy methods.

[57]  R. Thorpe,et al.  Systematic Comparison and Validation of Quantitative Real-Time PCR Methods for the Quantitation of Adeno-Associated Viral Products , 2015, Human gene therapy methods.

[58]  Randal J. Schoepp,et al.  Evaluation of ViroCyt® Virus Counter for Rapid Filovirus Quantitation , 2015, Viruses.

[59]  D. Gavin.  FDA statement regarding the use of adeno-associated virus reference standard materials. , 2015, Human gene therapy methods.

[60]  PiedraJose,et al.  Development of a Rapid, Robust, and Universal PicoGreen-Based Method to Titer Adeno-Associated Vectors , 2015 .

[61]  S. Berkowitz,et al.  Size-Exclusion Chromatograph (SEC) in Biopharmaceutical Process Development , 2015 .

[62]  Guideline on the quality, non-clinical and clinical aspects of gene therapy medicinal products , 2015 .

[63]  L. Zentilin,et al.  Manufacturing and characterization of a recombinant adeno-associated virus type 8 reference standard material. , 2014, Human gene therapy.

[64]  Christopher J Roberts,et al.  Therapeutic protein aggregation: mechanisms, design, and control. , 2014, Trends in biotechnology.

[65]  G. K. Raju,et al.  Understanding Pharmaceutical Quality by Design , 2014, The AAPS Journal.

[66]  M. R. Delgado Alvira,et al.  Absolute determination of single-stranded and self-complementary adeno-associated viral vector genome titers by droplet digital PCR. , 2014, Human gene therapy methods.

[67]  J. F. Wright,et al.  Product-Related Impurities in Clinical-Grade Recombinant AAV Vectors: Characterization and Risk Assessment , 2014, Biomedicines.

[68]  Nathan Cermak,et al.  Weighing nanoparticles in solution at the attogram scale , 2014, Proceedings of the National Academy of Sciences.

[69]  W. Xiao,et al.  A reliable and feasible qPCR strategy for titrating AAV vectors , 2013, Medical science monitor basic research.

[70]  J. Carpenter,et al.  Characterization and quantitation of aggregates and particles in interferon-β products: potential links between product quality attributes and immunogenicity. , 2013, Journal of pharmaceutical sciences.

[71]  S. Harvey,et al.  Biophysical and Ultrastructural Characterization of Adeno-Associated Virus Capsid Uncoating and Genome Release , 2012, Journal of Virology.

[72]  C. Mueller,et al.  Production and Discovery of Novel Recombinant Adeno‐Associated Viral Vectors , 2012, Current protocols in microbiology.

[73]  Arun Srivastava,et al.  Limitations of encapsidation of recombinant self-complementary adeno-associated viral genomes in different serotype capsids and their quantitation. , 2012, Human gene therapy methods.

[74]  K. Rapti,et al.  Quantification of AAV particle titers by infrared fluorescence scanning of coomassie-stained sodium dodecyl sulfate-polyacrylamide gels. , 2012, Human gene therapy methods.

[75]  L. Pease,et al.  Physical analysis of virus particles using electrospray differential mobility analysis. , 2012, Trends in biotechnology.

[76]  P. Fagone,et al.  Systemic errors in quantitative polymerase chain reaction titration of self-complementary adeno-associated viral vectors and improved alternative methods. , 2012, Human gene therapy methods.

[77]  M. R. Delgado Alvira,et al.  Analysis of particle content of recombinant adeno-associated virus serotype 8 vectors by ion-exchange chromatography. , 2012, Human gene therapy methods.

[78]  Jeff Mellen,et al.  High-Throughput Droplet Digital PCR System for Absolute Quantitation of DNA Copy Number , 2011, Analytical chemistry.

[79]  K. Brorson,et al.  Evaluation of electrospray differential mobility analysis for virus particle analysis: Potential applications for biomanufacturing , 2011, Journal of Virological Methods.

[80]  P. Fagone,et al.  Good manufacturing practice production of self-complementary serotype 8 adeno-associated viral vector for a hemophilia B clinical trial. , 2011, Human gene therapy.

[81]  J. F. Wright,et al.  Vector characterization methods for quality control testing of recombinant adeno-associated viruses. , 2011, Methods in molecular biology.

[82]  M. Audit,et al.  rAAV vector product characterization and stability studies. , 2011, Methods in molecular biology.

[83]  E. Ayuso,et al.  Production, purification and characterization of adeno-associated vectors. , 2010, Current gene therapy.

[84]  Patrick Garidel,et al.  Strategies for the Assessment of Protein Aggregates in Pharmaceutical Biotech Product Development , 2010, Pharmaceutical Research.

[85]  Terence R Flotte,et al.  Characterization of a recombinant adeno-associated virus type 2 Reference Standard Material. , 2010, Human gene therapy.

[86]  W. Jiskoot,et al.  Potential inaccurate quantitation and sizing of protein aggregates by size exclusion chromatography: essential need to use orthogonal methods to assure the quality of therapeutic protein products. , 2010, Journal of pharmaceutical sciences.

[87]  John P. Gabrielson,et al.  Precision of protein aggregation measurements by sedimentation velocity analytical ultracentrifugation in biopharmaceutical applications. , 2010, Analytical biochemistry.

[88]  J. Philo,et al.  A critical review of methods for size characterization of non-particulate protein aggregates. , 2009, Current pharmaceutical biotechnology.

[89]  J. F. Wright,et al.  Undetectable transcription of cap in a clinical AAV vector: implications for preformed capsid in immune responses. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[90]  Carl-Fredrik Mandenius,et al.  Bioprocess optimization using design‐of‐experiments methodology , 2008, Biotechnology progress.

[91]  J. F. Wright,et al.  Manufacturing and characterizing AAV-based vectors for use in clinical studies , 2008, Gene Therapy.

[92]  A. Pekar,et al.  Quantitation of aggregates in therapeutic proteins using sedimentation velocity analytical ultracentrifugation: practical considerations that affect precision and accuracy. , 2007, Analytical biochemistry.

[93]  J. Kleinschmidt,et al.  Development of AAV serotype-specific ELISAs using novel monoclonal antibodies. , 2007, Journal of virological methods.

[94]  H. Mizukami,et al.  Removal of empty capsids from type 1 adeno-associated virus vector stocks by anion-exchange chromatography potentiates transgene expression. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[95]  J. F. Wright,et al.  Identification of factors that contribute to recombinant AAV2 particle aggregation and methods to prevent its occurrence during vector purification and formulation. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[96]  M. S. Chapman,et al.  Large-scale production, purification and crystallization of wild-type adeno-associated virus-2. , 2004, Journal of virological methods.

[97]  Alan McClelland,et al.  Quantification of adeno-associated virus particles and empty capsids by optical density measurement. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[98]  Thomas Scheper,et al.  Flow cytometry in biotechnology , 2001, Applied Microbiology and Biotechnology.

[99]  D. Grimm,et al.  Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2 , 1999, Gene Therapy.

[100]  P Hajdú,et al.  [Analytical methods I]. , 1975, Arzneimittel-Forschung.